FY2025 · ended Dec 31, 2025 · Revenue $0, -100.0% YoY · Filed Mar 5, 2026
Compass Therapeutics, Inc. (CMPX) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $66.5 million. Free cash flow was -$49.2 million. As of Jun 30, 2026 it held $179.9 million in cash and investments and $9.6 million in total debt.
Revenue
$0
-100.0% vs prior year
Net income
$-66.49M
-34.7% vs prior year
Operating cash flow (TTM)
$-56.11M
-24.0% vs year-ago TTM
Free cash flow (TTM)
$-56.38M
-24.4% vs year-ago TTM
EPS
—
Dividend per share
None
Shares outstanding
180.09M
+30.2% vs prior year
Net cash
$170.25M
as of Jun 30, 2026
Operating margin
-6661.8%
FY 2024
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CMPX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1738021
- Former names
- Olivia Ventures, Inc. (until Jun 8, 2020)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $850,000 | — | — | — |
| Operating income | -$72.8M | -$56.6M | -$50.4M | -$41.7M | -$81.9M |
| Net income | -$66.5M | -$49.4M | -$42.5M | -$39.2M | -$82.2M |
| Operating cash flow | -$49.1M | -$44.9M | -$40.6M | -$34.1M | -$19.7M |
| Free cash flow | -$49.2M | -$44.9M | -$40.6M | -$34.3M | -$21.2M |
| Total assets | $219.6M | $140.4M | $156.9M | $199.6M | $153.8M |
| Total liabilities | $22.8M | $15.2M | $8.3M | $18.0M | $13.7M |
| Stockholders' equity | $196.8M | $125.2M | $148.5M | $181.6M | $140.1M |
| Cash and investments | $208.9M | $126.7M | $152.5M | $186.6M | $144.5M |
| Total debt | $9.8M | $6.6M | $1.7M | $2.9M | $4.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Sep 22, 2026 | Sep 22, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 1, 2026 | Jul 1, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Jun 23, 2026 | Jun 22, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2026 | Jun 10, 2026 |
All 359 Compass Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.